EA200400793A1 - Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции - Google Patents

Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции

Info

Publication number
EA200400793A1
EA200400793A1 EA200400793A EA200400793A EA200400793A1 EA 200400793 A1 EA200400793 A1 EA 200400793A1 EA 200400793 A EA200400793 A EA 200400793A EA 200400793 A EA200400793 A EA 200400793A EA 200400793 A1 EA200400793 A1 EA 200400793A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
norepinefrin
application
cognitive function
reverse capture
Prior art date
Application number
EA200400793A
Other languages
English (en)
Inventor
Фрэнклин Портер Баймастер
Дональд Ричард Гелерт
Дэвид Ли Маккинзи
Чарльз Ренкин Янг
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200400793A1 publication Critical patent/EA200400793A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Настоящее изобретение относится к селективным ингибиторам обратного захвата норэпинефрина, в частности к атомоксетину, ребоксетину и 2-алкилтиозамещенным феноксифенилпропиламинам, предназначенным для лечения нарушения познавательной функции, в том числе нарушения познавательной способности вследствие слабоумия, делирия и шизофрении.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400793A 2001-12-11 2002-11-27 Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции EA200400793A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
EA200400793A1 true EA200400793A1 (ru) 2004-10-28

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400793A EA200400793A1 (ru) 2001-12-11 2002-11-27 Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции

Country Status (26)

Country Link
US (1) US20050009925A1 (ru)
EP (1) EP1458368B1 (ru)
JP (1) JP2005517647A (ru)
KR (1) KR20040066895A (ru)
CN (1) CN1713900A (ru)
AU (1) AU2002352625A1 (ru)
BR (1) BR0213581A (ru)
CA (1) CA2467802A1 (ru)
CO (1) CO5590907A2 (ru)
CZ (1) CZ2004709A3 (ru)
DE (1) DE60223718T2 (ru)
EA (1) EA200400793A1 (ru)
EC (1) ECSP045145A (ru)
ES (1) ES2295435T3 (ru)
HR (1) HRPK20040528B3 (ru)
HU (1) HUP0402619A3 (ru)
IL (1) IL161989A0 (ru)
MX (1) MXPA04005716A (ru)
MY (1) MY136367A (ru)
NO (1) NO20042904L (ru)
NZ (1) NZ532065A (ru)
PL (1) PL369311A1 (ru)
SK (1) SK2442004A3 (ru)
TW (1) TW200300672A (ru)
WO (1) WO2003049724A1 (ru)
ZA (1) ZA200404274B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
GEP20043160B (en) * 1999-10-13 2004-01-26 Pfizer Products Inc Us Biaryl Ether Derivatives, Pharmaceutical Compositions Containing Them and Their Use as Monoamine Reuptake Inhibitors
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Also Published As

Publication number Publication date
CZ2004709A3 (cs) 2004-10-13
PL369311A1 (en) 2005-04-18
DE60223718T2 (de) 2008-10-30
CN1713900A (zh) 2005-12-28
EP1458368A1 (en) 2004-09-22
HRPK20040528B3 (en) 2006-03-31
MXPA04005716A (es) 2004-12-06
DE60223718D1 (de) 2008-01-03
ECSP045145A (es) 2004-07-23
WO2003049724A1 (en) 2003-06-19
NZ532065A (en) 2007-03-30
SK2442004A3 (en) 2004-12-01
ES2295435T3 (es) 2008-04-16
US20050009925A1 (en) 2005-01-13
JP2005517647A (ja) 2005-06-16
HRP20040528A2 (en) 2004-10-31
KR20040066895A (ko) 2004-07-27
CO5590907A2 (es) 2005-12-30
IL161989A0 (en) 2005-11-20
AU2002352625A1 (en) 2003-06-23
EP1458368B1 (en) 2007-11-21
HUP0402619A2 (hu) 2005-03-29
ZA200404274B (en) 2005-09-13
HUP0402619A3 (en) 2008-04-28
TW200300672A (en) 2003-06-16
NO20042904L (no) 2004-09-07
MY136367A (en) 2008-09-30
CA2467802A1 (en) 2003-06-19
BR0213581A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
EA200400793A1 (ru) Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции
BR0206422B1 (pt) mÉtodo e instalaÇço industrial para espessamento de lamas derivadas de tratamento de Águas atravÉs de floculaÇço-decantaÇço com floco lastreado.
EA200501251A1 (ru) Антинеопластические комбинации
NO20035609D0 (no) Fremgangsmåte for kontinuerlig naftabehandling
DE60101265D1 (de) Behandlung von augenschmerzen
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60220043D1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE60221670D1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
EA200600896A1 (ru) Способ лечения раздражения мочевого пузыря и чрезмерно активного мочевого пузыря
NL1021504A1 (nl) Waterstofbehandelingsproces.
DK1408976T5 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
DE60219687D1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
DE602005010258D1 (de) Behandlung von ballastwasser
PT102870A (pt) Metodo de tratamento de condensados
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
CY1106409T1 (el) Παραγωγα κινολινης
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
DE60103685D1 (de) Behandlung von Poriomania
ATE364389T1 (de) Verfahren zur herstellung von extrakten aus pelargonium sidoides und/oder pelargonium reniforme
EA200301299A1 (ru) Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DE602004004824D1 (de) Automatische Behandlung von Konversationsgruppen
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie